Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ion Beam Applications SA IBA ( (GB:0GZK) ) has issued an announcement.
IBA has introduced myQA MatriXX AiR, a high-resolution, wireless 2D ionization chamber array designed for patient-specific quality assurance in particle therapy, including both proton and carbon ion treatments. The system provides rapid, detailed 2D dose distribution readouts, enabling faster and more reliable verification of increasingly complex radiation treatment plans.
As the first commercially available wireless detector array for particle therapy PSQA, myQA MatriXX AiR streamlines setup and QA workflows while being FLASH-ready for ultra-high dose rate measurements and emerging techniques such as FLASH and ARC radiotherapy. By offering comprehensive QA coverage for current and next-generation particle-beam modalities, the launch strengthens IBA’s leadership in quality assurance and positions the company as a key partner for centers adopting advanced particle therapies.
The most recent analyst rating on (GB:0GZK) stock is a Hold with a EUR12.00 price target. To see the full list of analyst forecasts on Ion Beam Applications SA IBA stock, see the GB:0GZK Stock Forecast page.
More about Ion Beam Applications SA IBA
Ion Beam Applications SA (IBA), based in Louvain-la-Neuve, Belgium, is a global leader in particle accelerator technology and a major supplier of proton therapy systems, industrial sterilization solutions, radiopharmaceuticals and dosimetry equipment. Listed on Euronext and employing about 2,100 people worldwide, the certified B Corp focuses on advanced radiation therapies and quality assurance technologies for healthcare and industrial markets.
Average Trading Volume: 36,021
Current Market Cap: €400.4M
Learn more about 0GZK stock on TipRanks’ Stock Analysis page.